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To the Editor, 15 
Accurate risk stratification tools are paramount for optimal disease management. Patients with 16 
cardiovascular conditions, diabetes and cancer are most susceptible to COVID-19 complications 17 
leading to poor outcome1. These systemic diseases relate to enhanced fibrin formation and 18 
thromboinflammation. Indeed, severity of peripheral occlusive arterial disease correlates with the 19 
levels of both fibrinogen and its turnover measure D-dimer2. In severe COVID-19-infection, 20 
elevation of D-dimer and sepsis-induced coagulopathy (SIC), predicts poor prognosis. The 21 
incidence of venous thromboembolism (VTE) in patients with severe COVID-19 pneumonia is 22 
25% (!)3. Furthermore, endothelial injury inherent to vascular procedures may predispose to 23 
coagulopathy in COVID-19. The benefit of low-molecular-weight heparin therapy is protection of 24 
critically ill patients against VTE, as well as itsputative anti-inflammatory properties. Pulmonary 25 
 2
embolism (PE), triggered by severe infection, may be masked by the symptoms and signs of 1 
hypoxia in COVID-19. We advocate these considerations f r vascular specialists.  2 
A large retrospective Chinese cohort study1 emonstrated that the fibrin turnover-measure D-dimer 3 
exceeding 1 µg/mL on admission was associated with an increased ri k of in-hospital death (OR 20, 4 
95% CI 6.5-61.56, P < .0001) in COVID-19 patients. Another retrospective study4 assessed the 5 
benefits of anticoagulation on 28-day mortality, which does not appear to differ between heparin 6 
users (22%) and nonusers (mortality rates 30.3% vs 29.7%, respectively). However, patients with 6-7 
fold D-dimer levels (3 µg/mL) to normal clearly benefited from anticoagulation, translating to 8 
lower mortality (32.8% vs 52.4%, P = .017). Therefo, D-dimer levels on admission are 9 
particularly useful for risk stratification in COVID-19 patients (Fig. 1).  10 
Another important predictor of mortality is the International Society of Thrombosis and 11 
Haemostasis (ISTH) SIC-score5, which includes prothrombin time (ratio >1.5), platelet count (<100 12 
x109/l) and sequential organ function assessment (SOFA-score). In the above-mentioned study3, 13 
patients with ISTH SIC-score of ≥4 treated with anticoagulation showed again lower 28-day 14 
mortality rates than the untreated ones (40% vs 64%; P=.029). 15 
 16 
To guarantee the best outcomes for patients we sugge t that all medical professionals, including 17 
vascular specialists, adhere to ISTH guidelines on recognition and management of coagulopathy in 18 
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Figure 1. Outline of the algorithm for the management of coagulopathy in COVID-19 based on D-
dimer and SIC-score. DVT – deep vein thrombosis, PE – pulmonary embolism, LMWH – low 
molecular weight heparin, SIC – sepsis-induced coagul pathy. 
COVID-19 patient assessment:  
• D-dimer
• SIC-score
• 3-4 fold increase in D-dimer
• SIC-score ≥ 4:
o PT prolonged (INR > 1.4)
o Platelet count ≤ 100 x 109/L
Admit (even if not clinical concerns yet) 
and monitor lab once or twice daily
In all patients: start thromboprophylactic
LMWH – DVT is common! Raise LMWH 
dose if PE diagnosis is confirmed.
• D-dimer is not markedly raised
• SIC-score < 4:
o PT normal
o Platelet count normal
Monitor daily, 
if admission for clinical reasons
If worsening, use blood products to keep:
• platelet count > 20 x 109/L, if bleeding 
> 50 x 109/L 
• fibrinogen > 2.0 g/L
SIC-score:
Platelet count:
• 100-150 x 109/L → 1 point
• < 100 x 109/L      → 2 points
PT ratio:
• 1.2 – 1.4→ 1 point
• >1.4 → 2 points
SOFA score:
• 1   → 1 point
• ≥2 → 2 points
